DAPT Duration - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

Abstract

A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial
'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial
Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey
Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective
Dual antiplatelet therapy: how, how long, and in which patients?
Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison

Original Research

2019 Mar 9;9(3):e026053.

JOURNAL：BMJ Open.

Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)

Leonardi S, Franzone A, Piccolo R et al.

3261

Keywords: coronary heart disease; coronary intervention; ischaemic heart disease; myocardial infarction

FULL TEXT PDF